Sabra Health Care REIT, Inc.

Valuation Analysis

About the Company

Sabra Health Care REIT, Inc. en bref

Sabra Health Care REIT, Inc. (SBRA) is currently trading at 15,80 € with a market capitalization of 4,0 Md €. The trailing P/E ratio stands at 28.76x, with a forward P/E of 24.38x. The 52-week range spans from 14,97 € to 18,55 €; the current price is 14.8% below the yearly high. Year-over-year revenue growth stands at +21.7%. The net profit margin stands at 19.15%.

💰 Dividende

Sabra Health Care REIT, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

13 analystes évaluent Sabra Health Care REIT, Inc. (SBRA) au consensus : Acheter. L'objectif de cours moyen est de 19,85 €, soit un potentiel de +25.66% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 17,44 € à 21,79 €.

Sabra Health Care REIT, Inc. : la thèse d'investissement en détail

Sabra Health Care REIT, Inc. (SBRA) operates in the Real Estate — specifically REIT - Healthcare Facilities — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 21.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 63.74%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 19.15%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Le scénario baissier

Short interest sits at 16.03% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valorisation en contexte

At a PEG of 5.28, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here.

À surveiller

• The forward P/E of 24.38x is meaningfully below the trailing 28.76x — analysts expect earnings to step up; the next earnings release is the test.
• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 25.66% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

The price is in a transition zone relative to the moving averages — no clear signal.

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (16.03%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Sabra Health Care REIT, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.